Press releases

ORYZON announces first patient dosed in NCI-sponsored Phase I/II clinical trial of iadademstat plus immune checkpoint inhibitors in 1L extensive stage Small Cell Lung Cancer

ORYZON to provide corporate progress updates at several events in March-April

Oryzon announces publication of study on Phelan-McDermid Syndrome (PMS) patients, a form of autism, paving the way for a novel personalized medicine approach with vafidemstat

Oryzon defines Phase III Trial endpoints for Agitation and Aggression in BPD with input from new Clinical Advisory Board

ORYZON announces the voting results of February 2025 Extraordinary General Shareholders' Meeting

ORYZON reports financial results and corporate update for quarter ended December 31, 2024

ORYZON announces journal publication of final Phase IIa REIMAGINE results with vafidemstat in Psychiatry and Clinical Neurosciences

ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders’ Meeting

ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome

ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor